Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
2 (IPSC) Insider Trading Activity
Healthcare • Biotechnology • 152 employees
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Total Value
-$363,934.08
Total Shares
-125,598
Average Trade Value
-$30,327.84
Most Active Insider
Pfeiffenberger Brent
Total Activity: $350,564
Largest Single Transaction
$350,564
by Pfeiffenberger Brent on Dec 4, 2024
30-Day Activity
1 Transaction
Volume: 243,447 shares
Value: $350,564
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
President and CEO
Director, Officer
|
Dec 4, 2024 | 243,447 | $350,564 | 1,227,257 (-19.8%) | Payment of Exercise Price | |
SVP Finance Operations
Officer
|
Nov 4, 2024 | 283 | $347 | 317,147 (-0.1%) | Sale | |
Chief Operations Officer
Officer
|
Nov 4, 2024 | 1,033 | $1,267 | 135,130 (-0.8%) | Sale | |
SVP Finance Operations
Officer
|
Nov 1, 2024 | 16,611 | $20,930 | 317,430 (-5.2%) | Payment of Exercise Price | |
Chief Finanical Officer
Officer
|
Oct 14, 2024 | 60,148 | $0 | 60,148 (+100.0%) | Grant | |
Chief Scientific Officer
Officer
|
Oct 1, 2024 | 74,376 | $10,000 | 210,806 (+35.3%) | Grant | |
Director
|
Sep 12, 2024 | 5,000 | $7,657 | 5,000 (+100.0%) | Purchase | |
Chief Operations Officer
Officer
|
Aug 5, 2024 | 1,073 | $1,960 | 136,163 (-0.8%) | Sale | |
SVP Finance Operations
Officer
|
Aug 5, 2024 | 289 | $528 | 334,041 (-0.1%) | Sale | |
See Remarks
Officer
|
Jul 26, 2024 | 586 | $1,465 | 274,933 (-0.2%) | Sale | |
See Remarks
Officer
|
Jul 24, 2024 | 1,600 | $4,029 | 275,519 (-0.6%) | Sale | |
See Remarks
Officer
|
Jul 23, 2024 | 200 | $500 | 277,119 (-0.1%) | Sale |